There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
We assessed the efficacy and safety of brodalumab, a human monoclonal antibody against
interleukin-17 receptor A (IL17RA), in a phase 2, randomized, double-blind, placebo-controlled
study involving patients with psoriatic arthritis.
[1
]
From the Swedish Medical Center and University of Washington, Seattle (P.J.M.); Oregon
Health and Science University, Portland (A.D.); Stanford University, Palo Alto (M.C.G.),
Desert Medical Advances, Palm Desert (M.W.G.), and Amgen, Thousand Oaks (R.N., J.Y.F.,
N.E., A.N.) - all in California; University of Rochester Medical Center, Rochester,
NY (C.T.R.); and Laval University, Quebec, QC, Canada (A.D.B.).